Literatur
-
1
Butterworth R F.
Complications of cirrhosis. III. Hepatic encephalopathy.
J Hepatol.
2000;
32
171-180
-
2
Häussinger D.
Pathogenesis and treatment of chronic hepatic encephalopathy.
Digestion.
1998;
59 Suppl 2
25-27
-
3
Ferenci P.
Pathophysiology of hepatic encephalopathy.
Hepatogastroenterology.
1991;
38
371-376
-
4
Häussinger D, Laubenberger J, vom Dahl S. et al .
Proton magnetic resonance spectroscopy on human brain myo-inositol in hypo-osmolarity and hepatic encephalopathy.
Gastroenterology.
1994;
107
1475-1480
-
5
Häussinger D, Kircheis G, Fischer R. et al .
Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema.
J Hepatol.
2000;
32
1035-1038
-
6
Butterworth R F.
The astrocytic (‘peripheral-type’) benzodiazepine receptor: role in the pathogenesis of portal-systemic encephalopathy.
Neurochem Int.
2000;
36
411-416
-
7
Warskulat U, Görg B, Bidmon H. et al .
Ammonia-induced heme oxygenase-1 expression in cultured rat astrocytes and brain in vivo.
Glia 2002 (in press).
-
8
Warskulat U, Kreuels S, Müller H W. et al .
Identification of osmosensitive and ammonia-regulated genes in rat astrocytes by Northern blotting and differential display RT-PCR.
J Hepatol.
2001;
35
358-366
-
9
Schliess F, Görg B, Fischer R. et al .
Ammonia induces MK-801-sensitive nitration and phosphorylation of protein tyrosine residues in rat astrocytes.
FASEB J.
2001;
16
739-741 (10.1096/fj.01 - 0862fje)
-
10
Larsen F S, Gottstein J, Blei A T.
Cerebral hyperemia and nitric oxide synthase in rats with ammonia-induced brain edema.
J Hepatol.
2001;
34
548-554
-
11
Görg B, Foster N, Reinehr R. et al .
Benzodiazepin-induced protein tyrosine nitration in rat astrocytes.
Hepatology.
2002;
(submitted)
-
12
Hermenegildo C, Marcaida G, Montoliu C. et al .
NMDA receptor antagonists prevent acute ammonia toxicity in mice.
Neurochem Res.
1996;
21
1237-1244
-
13
Vogels B AP, Maas M AW, Daalhuisen J. et al .
Memantine, a non-competitive NMDA-receptor antagonist improves hyperammonia-induced encephalopathy and acute hepatic encephalopathy in rats.
Hepatology.
1997;
25
820-827
-
14
Timmermann L, Gross J, Kircheis G. et al .
Cortical origin of postural tremor in hepatic encephalopathy.
Neurology.
2002;
58
296-298
-
15 Conn H O. Quantifying the severity of hepatic encephalopathy. Conn HO, Bircher J Hepatic Encephalopathy: Syndromes and Therapies East Lansing, Michigan; Medi-Ed Press 1993: 13-26
-
16
Weissenborn K, Ennen J C, Schomerus H. et al .
Neuropsychological characterization of hepatic encephalopathy.
J Hepatol.
2001;
34 (5)
768-773
-
17
Kircheis G, Wettstein M, Timmermann L. et al .
Critical flicker frequency and quantification of low grade hepatic encephalopathy.
Hepatology.
2001;
35
357-366
-
18
Watanabe A, Kuwabara Y, Okita H. et al .
Computer-assisted quantitative neuropsychological tests for early detection of subclinical hepatic encephalopathy in patients with liver cirrhosis.
Res Commun Biol Psychology Psychiatry.
1997;
22
25-38
-
19
Groeneweg M, Quero J C, De Bruijn I. et al .
Subclinical hepatic encephalopathy impairs daily functioning.
Hepatology.
1998;
28
45-49
-
20
Kramer L, Tribl B, Gendo A. et al .
Partial pressure of ammonia versus ammonia in hepatic encephalopathy.
Hepatology.
2000;
31
30-34
-
21
Uribe M, Marquez M A, Garcia R amos G. et al .
Treatment of chronic portal systemic encephalopathy with vegetable and animal protein diets. A controlled crossover study.
Dig Dis Sci.
1982;
27
119-126
-
22
Horst D, Grace, ND, Conn H O. et al .
Comparison of dietary protein with an oral, branched chain-enriched amino acid supplement in chronic portal-systemic encephalopathy: a randomized controlled trial.
Hepatology.
1984;
4
279-287
-
23 Ferenci P, Müller C. Hepatic Encephalopathy: treatment. McDonald JWD, Bourroughs AK, Feagan BG Evidence based gastroenterology and hepatology BMJ Publishing group 1999 chapter 26
-
24
Uribe M, Campollo O, Vargas F. et al .
Acidifying enemas (lactitol and lactose) versus nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind randomized clinical trial.
Hepatology.
1987;
7
639-643
-
25
Kircheis G R, Nilius H, Berndt M. et al .
Therapeutic efficacy of L-ornithine-L-aspartate infusion concentrate in patients with liver cirrhosis and hepatic encephalopathy: A placebo-controlled double-blind study.
Hepatology.
1997;
25
1351-1360
-
26
Egberts E H, Schomerus H, Hamster W. et al .
Branched chain amino acids in the treatment of latent portosystemic encephalopathy. A double blind placebo-controlled crossover study.
Gastroenterology.
1985;
88
887-895
-
27
Naylor C D, O’Rourke K, Detsky A S. et al .
Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. A meta-analysis.
Gastroenterology.
1989;
97
1033-1042
-
28
Pomier-Layrargues G, Giguère J F, Lavoie J. et al .
Flumazenil in cirrhotic patients in hepatic coma: a randomized double-blind placebo-controlled crossover trial.
Hepatology.
1994;
19
32-37
-
29
Barbaro G, Di Lorenzo G, Soldini M. et al .
Flumazenil for Hepatic encephalopathy grade II and IV a in patients with cirrhosis: an Italian multicenter double-blind,placebo-controlled, cross-over study.
Hepatology.
1998;
28
374-378
-
30
Bresci G, Parisi G, Banti S.
Management of hepatic encephalopathy with oral zinc supplementation: a long term treatment.
Eur J Med.
1993;
2
414-416
-
31
Vásconez C, Elizalde J, Llach J. et al .
Helicobacter pylori, hyperammonemia and subclinical portosystemic encephalopathy: effects of eradication.
J Hepatol.
1999;
30
260-264
Prof. Dr. D. Häussinger
Medizinische Universitätsklinik
Moorenstraße 5
40225 Düsseldorf
Email: haeussin@uni-duesseldorf.de
